Search Results for:
Industry/research collaboration leads to fast-track for eye therapy
Last Tuesday, within the framework of the Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER- BBN), IBEC signed an agreement with pharmaceutical company Ferrer and the universities of Valladolid and the Basque Country to work towards developing a stem cell-based therapy to regenerate the surface of the eye.
“Células madre (y padre)” (Eng)
On October 13 El Periódico published an article about Nobel Prize winners John Gurdon and Shinya Yamanaka, who won the prize in medicine or physiology for their achievements in stem cell research. Towards the end of the piece, the author talks about the leading position held by Catalonia in research into stem cells, naming IBEC’s Ángel Raya as one of the region’s pioneers.
New NanoMed Spain document remembers late founder
Yesterday saw the launch in Madrid of a new NanoMed Spain publication, ‘Hoja por la Innovación en Nanomedicina en España’ (White Paper on Innovation in Nanomedicine in Spain), which diagnoses the country’s R&D&I capacities in the field so far and presents the potential opportunities, challenges and recommendations for the future.
“Nacen los primeros ratones sanos de ovulos procedentes de celulas madre” (Eng)
IBEC group leader Ángel Raya is quoted in articles in online newspapers Público and Materia this week, giving his expert opinion about some recent research in Japan. The scientists in … Read more
IBEC takes part in Connect-EU day
At the end of September representatives from IBEC, which coordinates and manages the Connect-EU Nanobio+Nanomed group, participated in the Connect-EU conference at Barcelona’s World Trade Centre.
Start of the first IBEC Junior Group Leaders
This month, the three candidates selected by the Scientific Advisory Board for IBEC’s new Tenure Track scheme started in their new capacity as Junior Group Leaders.
Positive review for MySpine
The IBEC-coordinated European project MySpine, which reached its midpoint at the end of August, received a positive appraisal at its first Annual Review in Brussels in June.